Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. 1996

T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
Department of Surgery, University of Minnesota, Minneapolis, USA.

The serious shortage of available donor organs for patients with end stage organ failure who are in need of solid organ transplantation has led to a heightened interest in xenotransplantation. The major barrier to successful discordant xenotransplantation is hyperacute rejection. Hyperacute rejection results from the deposition of preformed antibodies that activate complement on the luminal surface of the vascular endothelium, leading to vessel occlusion and graft failure within minutes to hours. Endogenous membrane-associated complement inhibitors normally protect endothelial cells from autologous complement -- however, these molecules are species-restricted and therefore are ineffective at inhibiting activated xenogeneic complement. To address the pathogenesis of hyperacute rejection in the pig-to-human combination, F1 offspring were generated from a transgenic founder animal that was engineered to express the human terminal complement inhibitor hCD59. High-level cell surface expression of hCD59 was detected in the hearts and kidneys of these transgenic F1 animals, similar to expression levels in human kidney tissue. The hCD59 was expressed on both large vessel and capillary endothelium. Ex vivo perfusion experiments, using human blood as the perfusate, were performed with transgenic porcine hearts and kidneys to evaluate the ability of hCD59 to inhibit hyperacute rejection. These experiments demonstrated that transgenic organs expressing hCD69 resisted hyperacute rejection, as measured by increased organ function for both the hearts and the kidneys, as compared with control pig organs. Hearts from hCD59-expressing animals demonstrated a five-fold prolongation in function compared with controls, 109.8 +/- 20.7 min versus 21.2 +/- 2.9 min (P = 0.164). The hCD59-expressing kidneys also demonstrated significantly prolonged function at 157.8 +/- 27.0 min compared with 60.0 +/- 6.1 min for controls (P = 0.0174). Deposition of C9 neoantigen In the vasculature of porcine organs perfused with human blood was markedly reduced in organs expressing hCD59. These studies demonstrate that C5b-9 plays an important role in hyperacute rejection of a porcine organ perfused with human blood and suggest that donor pigs transgenic for hCD59 may be an integral component of successful clinical xenotransplantation.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003186 Complement C9 A 63-kDa serum glycoprotein encoded by gene C9. Monomeric C9 (mC9) binds the C5b-8 complex to form C5b-9 which catalyzes the polymerization of C9 forming C5b-p9 (MEMBRANE ATTACK COMPLEX) and transmembrane channels leading to lysis of the target cell. Patients with C9 deficiency suffer from recurrent bacterial infections. C9 Complement,Complement 9,Complement Component 9,C9, Complement,Complement, C9,Component 9, Complement
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts

Related Publications

T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
March 2022, Xenotransplantation,
T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
January 2022, Experimental eye research,
T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
August 1995, Transplantation proceedings,
T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
January 2001, Transplantation proceedings,
T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
January 1997, Transplantation proceedings,
T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
November 2000, Transplantation proceedings,
T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
November 2005, Zhonghua yi xue za zhi,
T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
September 2000, Surgery,
T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
March 2011, Korean circulation journal,
T J Kroshus, and R M Bolman, and A P Dalmasso, and S A Rollins, and E R Guilmette, and B L Williams, and S P Squinto, and W L Fodor
March 1998, Transplantation,
Copied contents to your clipboard!